Inclusion Criteria:

- Age > 18 years

- histologically proven malignant tumor

- documented decision of treatment with i) a chemotherapeutic regimen with capecitabine
(alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase
inhibitor, iii) or an non-steroidal aromatase inhibitor

- ambulatory treated subject

- Subject who accept to use MEMS monitors to automatically compile their drug dosing
histories

- Written informed consent

Exclusion Criteria:

- any severe concomitant wich makes it undesirable for the patient to participate in
the study or which would jeopardize adherence with trial protocol

- patient who does not agreed to participate the program